TICKERNERD
Menu
GNPXGNPXHealthcare · Biotechnology

GNPX Stock Forecast: Genprex, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$3.45

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap
$2.8M
Ticker Nerd rank
9 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$4.5M
Net income−$4.4M
Free cash flow−$5.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

GNPX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Genprex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
42
Volatility
39
Accruals
34
Revisions
25
Issuance
23
Quality
17
Value
5
Momentum
2

Size (98): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GNPX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNPX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 May 2024HC Wainwright & Co.ReiteratesBuy$10
15 May 2024HC Wainwright & Co.ReiteratesBuy$10
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Mar 2024HC Wainwright & Co.InitiatesBuy—
30 Jan 2023Dawson JamesInitiatesBuy$3.00
14 Sept 2018Maxim GroupInitiatesBuy$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GNPX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GNPX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Genprex, Inc. (GNPX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−203.9%

Higher than 7% of US stocks

Return on assets
−94.5%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Genprex, Inc. (GNPX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Genprex, Inc. has a market value of $2.8M and an enterprise value of −$12.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.6M.

  • Shares outstanding: 504,935.

  • Trailing P/E: 0.1×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Genprex, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

GNPX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNPXGenprex, Inc.$2.8M
9
CLDICalidi Biotherapeutics, Inc.$2.8M
23
ONCOOnconetix, Inc.$2.8M
16
BCABBioAtla, Inc.$2.9M
—
SILOSilo Pharma, Inc.$2.9M
24
TCRTAlaunos Therapeutics, Inc.$2.9M
28
CMNDClearmind Medicine, Inc.$2.7M
6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Genprex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GNPX news & analysis

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Genprex, Inc. announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company presentation will highlight its lead clinical oncology program and preclinical diabetes program.

Why it matters — The presentation gives Genprex watchers a potential opportunity to hear directly from leadership about the company's clinical oncology and preclinical diabetes programs at a major investment conference.

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

PRNewsWire · 18 Aug 2026positive

Genprex announced it has entered into a development and manufacturing agreement with a leading U.S.-based clinical and commercial CDMO to initiate manufacturing scale-up of its diabetes gene therapy program. The collaboration is intended to accelerate manufacturing processes for IND-enabling preclinical studies and future clinical trials, allowing the therapeutic candidate to transition from research-grade production to clinical and commercial-ready output.

Why it matters — GNPX watchers would care because the agreement moves the company's diabetes gene therapy candidate toward clinical and commercial-ready production, a key step in advancing the program toward IND-enabling studies and future clinical trials.

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

PRNewsWire · 3 Aug 2026positive

Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, the collaboration intends to use TROP2 as a biomarker to refine patient identification and optimize trial selection criteria.

Why it matters — The collaboration with Roche could help refine biomarker-driven patient selection, potentially advancing Genprex's precision-medicine approach in its NSCLC clinical program.

FAQ

Frequently asked questions about GNPX stock

Is GNPX stock a buy right now?

Of the 1 analysts covering Genprex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genprex, Inc. 9 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNPX?

As at 19 Sept 2026, Genprex, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the GNPX stock forecast for 2030?

No analyst covering Genprex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNPX are extrapolating price history, which says nothing about the business.

What does Genprex, Inc. do?

Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes.

What is the latest news on GNPX?

The most recent item we track (PRNewsWire, 8 Sept 2026): "Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Genprex, Inc. announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company presentation will highlight its lead clinical oncology program and preclinical diabetes program.

Company

About Genprex, Inc.

Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The company’s current pipeline centers on gene-based technologies designed to deliver therapeutic genes using non-viral and nanoparticle delivery approaches. Its oncology work includes REQORSA immunogen therapy, which is being developed for lung cancer, while its diabetes program includes GPX-002, a gene therapy candidate aimed at addressing metabolic disease. Genprex Inc. operates in the healthcare and biotechnology sectors, where it contributes to the broader field of advanced genetic medicine and targeted treatment development. The common stock represents investor exposure to a company whose business is built around translational research, drug development, and clinical-stage innovation in diseases with significant unmet medical need.

CEO Mr. Ryan M. Confer M.S. · 13 employees · United States · https://www.genprex.com